Australian researchers are scaling up lab-grown blood production in a $2.5 million collaboration between the Australian Red Cross’ Lifeblood and the University of Queensland, offering a potential lifeline for individuals with rare blood types like Joe Fa’agase, who is one of 14 people in Australia with the JK null blood type. While Lifeblood currently grows functional red blood cells from donor stem cells, the existing manual process takes three weeks to produce just a few teaspoons at a cost of $70,000.
The Cost and Scale Hurdle of Manufacturing Lab-Grown Blood
Producing lab-grown red blood cells at a commercial scale remains expensive and technically demanding. University of Queensland biomedical engineer Dr Mark Allenby said that while current lab-grown cells are safe and have been successfully transfused into humans, scaling the production is the primary barrier. According to Allenby, producing one trillion red blood cells currently requires culture flasks covering an area similar to a tennis court, driving the cost to about $1 million per blood transfusion bag. The Brisbane-based research team aims to develop technologies that can grow these cells 10 to 100 times more cost-efficiently.
Lifeline for Rare Blood Types and Remote Patients
Patients with exceptionally rare blood profiles face significant hurdles during medical emergencies when standard inventory falls short. Joe Fa’agase, a 32-year-old, shares the rare Jk(a-b-) blood type with his three brothers, requiring specialized stock to be stored in Sydney. Scaled-up manufacturing could alleviate supply vulnerabilities for newborns needing closely matched transfusions and individuals in remote areas. Professor Simon Cool, CEO of Smart CRC, noted that the partnership aims to accelerate the delivery of these medical manufacturing solutions directly to Australian patients.
Clinical Trials and the Future of Blood Donation
Clinical trials for manufactured blood products remain at least five years away, and researchers emphasize that the technology is not designed to replace traditional human donations. Lifeblood researcher Dr Becky Griffiths confirmed that lab-grown red cells would not be to ever replace donations. As the University of Queensland and Lifeblood partnership progresses, the focus remains on making synthetic blood financially and logistically viable for routine medical application.
Common Questions About Lab-Grown Blood Production
How much does lab-grown blood currently cost to produce?
Current manual production methods cost approximately $70,000 to yield just a few teaspoons over a three-week period, translating to roughly $1 million per transfusion bag at scale.
Who will benefit most from manufactured blood?
Newborns requiring precise matches, individuals living in remote regions, and patients with rare blood types—such as the 14 Australians identified with the JK null type—stand to benefit the most.
Will lab-grown blood replace human donors?
No. Lifeblood researchers state that manufactured blood is intended to supplement existing supplies for emergency and specialized medical needs rather than replace human blood donations.
When will lab-grown blood be available for patients?
Clinical trials are currently estimated to be at least five years away.
Keep reading